HUMAN METABOLOME TECHNOLOGIES, INC. Human Metabolome Technologies, Inc. Stock
Equities
6090
JP3794530000
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 651 JPY | -1.66% |
|
-0.15% | +1.72% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.22B 7.84M | Sales 2023 | 1.3B 8.32M | Capitalization | 4.42B 28.35M |
|---|---|---|---|---|---|
| Net income 2022 | 267M 1.71M | Net income 2023 | 285M 1.83M | EV / Sales 2022 | 2.48 x |
| Net cash position 2022 | 1.27B 8.15M | Net cash position 2023 | 1.43B 9.16M | EV / Sales 2023 | 2.31 x |
| P/E ratio 2022 |
16.1
x | P/E ratio 2023 |
15.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
1.34% | Free-Float | 80.56% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.66% | ||
| 1 week | -0.15% | ||
| Current month | -0.46% | ||
| 1 month | -1.51% | ||
| 3 months | -0.31% | ||
| 6 months | -3.56% | ||
| Current year | +1.72% |
1 week
645.00
669.00
1 month
640.00671.00
Current year
624.00720.00
1 year
588.00794.00
3 years
545.001 044.00
5 years
453.002 032.00
10 years
453.002 890.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 55 | 18-02-28 | |
Tomomi Ishihara
ADM | Chief Administrative Officer | - | - |
Takaomi Fukuhara
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yasuhiro Ohata
BRD | Director/Board Member | 59 | 20-06-30 |
| Corporate Officer/Principal | 49 | 05-06-30 | |
Toshio Nagae
BRD | Director/Board Member | 80 | 17-06-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 651 | -1.66% | 10 700 |
| 24-05-20 | 662 | +0.46% | 8,000 |
| 24-05-17 | 659 | -0.15% | 2,000 |
| 24-05-16 | 660 | -0.30% | 4,700 |
| 24-05-15 | 662 | +1.53% | 6,500 |
Delayed Quote Japan Exchange, May 21, 2024 at 01:56 am EDT
More quotes
Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
Calendar
2024-08-07
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.72% | 25.09M | |
| +40.50% | 54.04B | |
| +45.55% | 41.96B | |
| -1.30% | 41.92B | |
| -7.20% | 28.35B | |
| +12.49% | 26.35B | |
| -21.12% | 19B | |
| +6.66% | 13B | |
| +29.02% | 12.28B | |
| +25.95% | 12.19B |
- Stock Market
- Equities
- 6090 Stock